TITLE

FDA: LDL-lowering drug may be linked to cancer risk

PUB. DATE
September 2008
SOURCE
Hem/Onc Today;9/10/2008, Vol. 9 Issue 16, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports on a warning issued by the U.S. Food and Drug Administration (FDA) about the possible relationship between combination simvastatin plus ezetimibe and an increased incidence of cancer. According to preliminary data from the Simvastatin Ezetimibe Aortic Stenosis (SEAS) trial, the combination of simvastatin and ezetimibe lowered the low-density lipoprotein (LDL) levels of patients with mild to moderate aortic stenosis.
ACCESSION #
34154531

 

Related Articles

  • FDA Approves Perjeta (Pertuzumab) for People With HER2-Positive Metastatic Breast Cancer.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article informs that the U.S. Food and Drug Administration has approved Perjeta which has been developed by Genentech Inc. It further informs that Perjeta is used in combination with Herceptin and docetaxel for the treatment of breast cancer. It mentions the side effects of Perjeta which...

  • FDA Actions. Elliott, William T. // Clinical Cardiology Alert;Oct2008 Pharmacology Watch, p2 

    The article reports on a warning issued by the U.S. Food & Drug Administration in 2008 regarding the use of simvastatin in patients who are taking amiodarone. It is noted that more than 20 mg of simvastatin plus amiodarone puts patient at higher risk for rhabdomyolysis since amiodarone inhibits...

  • New combination.  // Formulary;Aug2007, Vol. 42 Issue 8, p462 

    The article focuses on the approval of combined calcium-channel blocker and antagiotensin II receptor antagonist in treating hypertension in the U.S. The amlodipine/valsartan combination therapy was given approval by the Food and Drug Administration on June 20, 2007. It is not indicated for the...

  • Rhabdomyolysis risk with simvastatin plus amiodarone.  // Reactions Weekly;8/16/2008, Issue 1215, p2 

    The article reports on the warning issued by the U.S. Food and Drug Administration that notifies the public of an increased risk of rhabdomyolysis with a combined use of simvastatin and amiodarone. The disease, a condition of muscle injury, can potentially lead to kidney failure or even death....

  • US FDA panel advises banning of two asthma drugs.  // Reactions Weekly;2/7/2009, Issue 1238, p2 

    The article focuses on a marketing ban on the long-acting Î’-agonists (LABAs) formoterol and salmeterol recommended by a U.S. Food & Drug Administration (FDA) panel. The FDA panel, however, recommends that combination products, such as budesonide/formoterol and salmterol/fluticasone, continue...

  • US FDA reviewing safety of ezetimibe/simvastatin.  // Reactions Weekly;8/30/2008, Issue 1217, p2 

    The article reports on the safety review by the U.S. Food and Drug Administration (FDA) of ezetimibe (Vytorin) and simvastatin after receiving a report from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial about a possible association between ezetimibe use and increased cancer risk....

  • AVADO: Bevacizumab plus docetaxel met primary endpoint for advanced breast cancer.  // Hem/Onc Today;2/25/2008, Vol. 9 Issue 3, p1 

    The article focuses on a press release announcing the phase-3 AVADO results which states that progression-free survival improved with combination bevacizumab and docetaxel therapy in previously untreated patients with recurrent or metastatic HER2-negative breast cancer. The announcement was made...

  • FDA Approves A New Chemo Combination For Lung CA. Bauer, Jeff; Hurley, Mary Lou // RN;Nov2006, Vol. 69 Issue 11, p51 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of the use of a drug combination for treating non-small cell lung cancer (NSCLC). Bevacizumab has received FDA approval in 2006 to be used in combination with carboplatin and paclitaxel. The combination is an...

  • FDA Announces Vytorin Investigation.  // Travel Medicine Advisor;Oct2008 Supplement, p1 

    The article cites a report from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial which will be investigated by the U.S. Food and Drug Administration. The report stated a link between the drug Vytorin, a combination between simvastatin and ezetimibe, and presented preliminary data...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics